Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02365493

Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection — CAMERA2  

Methicillin-Resistant Staphylococcus Aureus Clinical Trial

Official title:
CAMERA 2 - Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection - An Investigator-initiated, Multi-centre, Parallel Group, Open Labelled Randomised Controlled Trial

Clinical Trial Summary

The aim of this clinical trial is to determine whether a novel combination antibiotic treatment (vancomycin/daptomycin + beta-lactam) is superior to the standard antibiotic treatment (vancomycin/daptomycin) for hospitalised adults with Methicillin Resistant Staphylococcus aureus bacteraemia. The hypothesis is that the addition of beta-lactam antibiotics (these are antibiotics from the penicillin family) to the standard therapy will lead to more efficient bacterial killing and hence lead to faster clearance of bacteria from the blood stream and other areas of infection, thereby reducing the risk of the spread of infection and death.

The study design is an investigator-initiated, multi-centre, open-label, randomised controlled trial. This will include 440 participants diagnosed with Methicillin Resistant Staphylococcus aureus bacteraemia recruited over a period of 4 years (July 2015 - June 2019) from within Infectious Diseases inpatient units across 21 hospital sites including 18 from within Australia and 3 located in Singapore. Participation will be voluntary and subject to informed consent. The participants will be randomised 1:1 to either the standard therapy group or combination therapy group. The combination therapy will include a treatment of intravenous beta-lactam for the first 7 days of treatment, in addition to the standard treatment (either vancomycin or daptomycin). The primary outcome measure will be complication-free survival 90 days post randomisation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02365493
Study type Interventional
Source Menzies School of Health Research
Contact
Status Terminated
Phase Phase 3
Start date August 26, 2015
Completion date October 24, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT05529173 - Povidone-Iodine for Nasal Decolonization Phase 4
Completed NCT00980980 - Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs) N/A
Recruiting NCT03412500 - Vancomycin Dosage Adjustment for MRSA Infections Phase 4
Recruiting NCT02566928 - Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence Phase 4
Terminated NCT01196169 - Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty Phase 4
Completed NCT00996112 - Primary Care Management of Community-Acquired, Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Infections N/A
Not yet recruiting NCT00773864 - Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community-Healthcare Workers N/A
Not yet recruiting NCT00773799 - Mastering Hospital Antimicrobial Resistance and Its Spread Into the Community N/A
Completed NCT01350479 - Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers N/A
Recruiting NCT03637400 - Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment Phase 2
Completed NCT01200654 - Population Pharmacokinetics of Linezolid Phase 4
Withdrawn NCT00856089 - Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization Phase 4
Recruiting NCT04171817 - Animal-Assisted Visitation Program Chlorhexidine Trial Phase 4
Completed NCT00324922 - Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis Phase 3
Completed NCT02814916 - Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Phase 3
Withdrawn NCT00713674 - Comparison of Decolonization of Methicillin-resistant Staphylococcus Aureus (MRSA) Using Theraworx N/A
Not yet recruiting NCT05632315 - PMT for MDRO Decolonization Phase 2
Not yet recruiting NCT01356472 - Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Ventilator-associated Pneumonia Phase 4
Completed NCT03886623 - A Systematic Oral Care Program in Post-Mechanically Ventilated, Post-Intensive Care Patients N/A
Completed NCT01141101 - Risk Factors for Early Infant Colonization With Methicillin-Resistant Staphylococcus Aureus N/A